From the Journals

Two-dose HPV vaccine trials in teens show effective immunological responses

Publish date: May 12, 2017
By
Catherine Cooper Nellist

 

FROM VACCINE

Two-dose human papillomavirus (HPV) vaccine trials appear to show effective immunological responses in teen girls, said Maddalena D’Addario of the University of Bern, Switzerland, and her associates.

In seven controlled trials in 11 countries that directly compared two-dose and three-dose HPV vaccine schedules, teen girls receiving two doses of HPV vaccine with a 6-month interval between them had noninferior antibody responses to HPV16 and HPV18 for at least 2 years, compared with girls receiving three doses.

BVDC/Fotolia.com
In one study in India, teen girls who received two or three doses of HPV vaccines developed no persistent new HPV infections. When comparing different two-dose schedules, those with longer intervals between doses had higher geometric mean concentrations of antibodies.

National Cancer Institute
A limitation to this study is that there is no established immune correlate of protection, so the clinical significance of HPV antibody concentrations is uncertain, the researchers cautioned.

Read more in the journal Vaccine (2017 May 19;35[22]:2892-901).

Recommended Reading

HIV vaccine could prevent 30 million cases by 2035
MDedge Internal Medicine
Shingles vaccine deemed effective in people with autoimmune disease
MDedge Internal Medicine
Anthony Fauci faces the ‘perpetual challenge’ of emerging infections
MDedge Internal Medicine
Make assessment of immunization status of older adults routine
MDedge Internal Medicine
WHO’s malaria pilot vaccine: No silver bullet, but a potential strike at malaria’s heart
MDedge Internal Medicine
U.S. yellow fever vaccine stocks could be depleted within months
MDedge Internal Medicine
Two doses HPV vaccine are as good as three against genital warts
MDedge Internal Medicine
Flu shots may spark immune adverse events in PD-1 blockade for NSCLC
MDedge Internal Medicine
Adult vaccination is low, with minimal improvement in recent years
MDedge Internal Medicine
Topical imiquimod boosted response to intradermal hepatitis B vaccine
MDedge Internal Medicine